NCT03423628CompletedPhase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 159 (actual)
- First submitted
- 28 Nov 2017
- Start date
- 2 Apr 2018
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Glioblastoma
- NCT number
- NCT03423628
- EudraCT number
- 2017-002451-28
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 159
- From 2 Apr 2018 to the primary completion date, 31 Aug 2026
- 10 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
This page is information, not medical advice. Discuss any trial with your doctor.